Abstract
Metastasis of breast cancer occurs primarily through the lymphatic system, and the extent of lymph node involvement is a key prognostic factor for the disease. Whereas the significance of angiogenesis for tumor progression has been well documented, the ability of tumor cells to induce the growth of lymphatic vessels (lymphangiogenesis) and the presence of intratumoral lymphatic vessels have been controversial. Using a novel marker for lymphatic endothelium, LYVE-1, we demonstrate here the occurrence of intratumoral lymphangiogenesis within human breast cancers after orthotopic transplantation onto nude mice. Vascular endothelial growth factor (VEGF)-C overexpression in breast cancer cells potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes and to lungs. The degree of tumor lymphangiogenesis was highly correlated with the extent of lymph node and lung metastases. These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lee, F.C. & Tilghmann, R.C. Lymph vessels in rabbit carcinoma, with a note on the normal lymph vessel structure of the testis. Arch. Surg. 26, 602–616 (1933).
Gilchrist, R.K. Surgical management of advanced cancer of the breast. Arch. Surg. 61, 913–929 (1950).
Zeidman, I., Copeland, B.E. & Warren, S. Experimental studies on the spread of cancer in the lymphatic system. II. Absence of a lymphatic supply in carcinomas. Cancer 8, 123–127 (1955).
Tanigawa, N. et al. Experimental study on lymphatic vascular changes in the development of cancer. Lymphology 14, 149–154 (1981).
Folkman, J. Angiogenesis and tumor growth. N. Engl. J. Med. 334, 921 (1996).
Leu, A.J., Berk, D.A., Lymboussaki, A., Alitalo, K. & Jain, R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324–4327 (2000).
Oh, S.J. et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188, 96–109 (1997).
Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423–1425 (1997).
Kaipainen, A. et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92, 3566–3570 (1995).
Jussila, L. et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58, 1599–1604 (1998).
Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).
Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9–22 (1999).
Achen, M.G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 95, 548–553 (1998).
Kurebayashi, J. et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. 90, 977–981 (1999).
Salven, P. et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153, 103–108 (1998).
Andre, T. et al. VEGF, VEGF-B, VEGF-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer 86, 174–181 (2000).
Akagi, K. et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83, 887–891 (2000).
Niki, T. et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 6, 2431–2439 (2000).
Ohta, Y., Nozawa, H., Tanaka, Y., Oda, M. & Watanabe, Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 119, 804–813 (2000).
Shushanov, S. et al. VEGF-C and VEGFR3 expression in human thyroid pathologies. Int. J. Cancer 86, 47–52 (2000).
Bunone, G. et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol 155, 1967–1976 (1999).
Fellmer, P.T. et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126, 1056–1061 (1999).
Yonemura, Y. et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 5, 1823–1829 (1999).
Ohta, Y. et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 81, 54–61 (1999).
Eggert, A. et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6, 1900–1908 (2000).
Tsurusaki, T. et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J. Cancer 80, 309–313 (1999).
Price, J.E., Polyzos, A., Zhang, R.D. & Daniels, L.M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50, 717–721 (1990).
Hoffman, R.M. Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev. 17, 271–277 (1998).
Joukov, V. et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898–3911 (1997).
Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789–801 (1999).
Fisher, B. & Fisher, E.R. Role of the lymphatic system in dissemination of tumor. in Lymph and the lymphatic system (ed. Mayerson, H.S.) 324 (Charles C. Thomas, Springfield, Illinois, 1968).
Skobe, M. & Detmar, M. Structure, function and molecular control of the skin lymphatic system. J. Invest. Dermatol. Symp. Proceed. 5, 14–19 (2000).
Evans, H.M. On the occurence of newly-formed lymphatic vessels in malignant growths. John Hopkins Med. J. 19, 232 (1908).
Reichert, F.L. The regeneration of the lymphatics. Arch. Surg. 13, 871–881 (1926).
Witte, M.H., Way, D.L., Witte, C.L. & Bernas, M. Lymphangiogenesis: mechanisms, significance and clinical implications. EXS 79, 65–112 (1997).
Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
Leak, L.V. Electron microscopic observations on lymphatic capillaries and the structural components of the connective tissue-lymph interface. Microvasc. Res. 2, 361–391 (1970).
Pullinger, B.D. & Florey, H.W. Some observations on the structure and functions of lymphatics: their behavior in local edema. Br. J. Exp. Pathol. 16, 49 (1935).
Jain, R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47, 3039–3051 (1987).
Baxter, L.T. & Jain, R.K. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res. 40, 246–263 (1990).
Jain, R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9, 253–266 (1990).
Detmar, M. et al. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am. J. Pathol. 156, 159–167 (2000).
Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. & Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222–1227 (1997).
St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197–1202 (2000).
Acknowledgements
We thank R. Timpl for the anti-collagen XVIII antibody; M. Swartz and V. Joukov for helpful discussions; and H. Oura for technical assistance. This work was supported by the Human Frontier Science Program (to M.S.), Deutsche Forschungsgemeinschaft (to T.H.), by NIH/NCI grants CA69184 and CA86410 (to M.D.) and by the Cutaneous Biology Research Center through the Massachusetts General Hospital/Shiseido Co. Ltd. Agreement (to M.D.). D.J. is supported by the UK Medical Research Council and by a project grant (00-311) from the Association for International Cancer Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skobe, M., Hawighorst, T., Jackson, D. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7, 192–198 (2001). https://doi.org/10.1038/84643
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/84643
This article is cited by
-
Toward Characterizing Lymphatic Vasculature in the Mammary Gland During Normal Development and Tumor-Associated Remodeling
Journal of Mammary Gland Biology and Neoplasia (2024)
-
Loss of TTC17 promotes breast cancer metastasis through RAP1/CDC42 signaling and sensitizes it to rapamycin and paclitaxel
Cell & Bioscience (2023)
-
Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy
Nature Communications (2023)
-
The exit of nanoparticles from solid tumours
Nature Materials (2023)
-
New insights into the correlations between circulating tumor cells and target organ metastasis
Signal Transduction and Targeted Therapy (2023)